OKYO

OKYO Pharma Ltd - New

Stock NASDAQ – Stock Market Prices, News & Analysis

OKYO Pharma Ltd develops pharmaceutical treatments for eye diseases, focusing on innovation and the effectiveness of therapeutic solutions.

$ 1.65
2.48 %

OKYO Pharma Ltd - New

$ 1.65
2.48 %
OKYO

OKYO Pharma Ltd develops pharmaceutical treatments for eye diseases, focusing on innovation and the effectiveness of therapeutic solutions.

Price history of OKYO Pharma Ltd - New
Price history of OKYO Pharma Ltd - New

Performance & Momentum

6 Months 27.68 %
1 Year 8.00 %
3 Years 18.25 %
5 Years 46.00 %

Strategic Analysis

OKYO Pharma Ltd - New • 2026

OKYO Pharma positions itself as an innovative player in the U.S. pharmaceutical sector, specializing in the development of treatments for eye diseases, a promising segment with strong therapeutic value. Its differentiation is based on the effectiveness of the targeted solutions it offers, with a model centered on advanced clinical research in a niche area that is often underexploited.

Strengths
  • Focus on eye diseases, a sector with significant unmet medical need
  • Innovative approach with differentiated and specific treatments
  • Presence in the U.S. market, a favorable environment for biotech
Weaknesses
  • Volatile share performance with significant declines over the medium and long term
  • Weak current momentum, reflecting challenges in convincing investors
Momentum

Current momentum reflects moderate stock-market dynamics, weighed down by financial and clinical results that are still not sufficiently mature. Despite a positive rebound over one year, the medium-term trend remains uncertain, calling for caution and vigilance regarding the progress of the next stages of its development.

Similar stocks to OKYO Pharma Ltd - New

Was this page helpful?

Your feedback helps us improve our research.

Take control
of your investments

Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.

  • Real-time multi-portfolio tracking
  • AI analysis of your positions
  • Counter your cognitive biases
Anantys Invest on iPhone